Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Verdicts against social media companies carry consequences. But questions linger - 2Collection of 7,000-year-old ostrich eggs discovered under sand dunes in southern Israel
- 3Flourishing in a Remote Workplace: Individual Techniques
- 4What's A Decent FICO rating?
- 5Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- Meet Beef the bulldog, who takes slow walks with his 78-year-old friend
- Ancient meditation practices find new life in modern religious communities across America
- Report: Thailand strikes deal with Iran for safe passage of Hormuz
- 10 Hints and Deceives to Expand Cell Phone Information Use: Capitalize on Your Information
- Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables
- Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- Monetary Security: Building Serious areas of strength for an Establishment
- Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
